Wrap Text
ASPI to hold capital markets day on September 8
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASPI TO HOLD CAPITAL MARKETS DAY ON SEPTEMBER 8
DALLAS, July 28, 2026 — ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the "Company"), an
advanced materials company focused on developing technologies and processes for the production of
critical materials used in multiple industries, today announced that it will hold a Capital Markets Day in
London on Tuesday, September 8, 2026, beginning at 10:00 a.m. ET (3:00 p.m. BST).
During the event, leadership will provide a comprehensive update on the Company's strategic direction
and commercial momentum, including a deep dive into nuclear medicine, electronic gases, and nuclear
fuels, as well as the long-term market opportunity in each.
Event Access and Registration
The Capital Markets Day presentation and formal Q&A will take place from 10:00 a.m. to 12:30 p.m. ET
(3:00 p.m. to 5:30 p.m. BST). While in-person attendance in London is by invitation only, the public is
invited to join via live webcast.
Webcast registration: Please click here
Presentation materials will be available at the start of the live webcast at
https://ir.aspisotopes.com/news-events. A replay will be available on the Company's website following
the event.
About ASP Isotopes Inc.
ASP Isotopes is developing a differentiated isotope enrichment platform to strengthen global supply
chain access to critical materials used in nuclear medicine, next-generation semiconductors, and
nuclear energy. The Company's proprietary technologies, the Aerodynamic Separation Process ("ASP
technology") and Quantum Enrichment ("QE technology"), are designed to enable the production of
isotopes for a range of industrial and advanced technology applications. ASP Isotopes operates isotope
enrichment facilities in Pretoria, South Africa, focused on the enrichment of low atomic mass elements,
or light isotopes. For more information, please visit www.aspisotopes.com.
Important Additional Information and Where to Find It
In connection with the proposed merger and related transactions (the "Proposed Transactions")
involving ENDRA Life Sciences Inc. ("ENDRA"), ASP Isotopes, Renergen, a subsidiary of ASP Isotopes
("Renergen"), and Noble Africa, a subsidiary of ASP Isotopes and holding company for Renergen
("Noble Africa"), ENDRA intends to file relevant materials with the U.S. Securities and Exchange
Commission (the "SEC"), including a registration statement on Form S-4 (the "Form S-4") that will
contain a proxy statement (the "Proxy Statement") and prospectus. This communication is not a
substitute for the Form S-4, the Proxy Statement or for any other document that ENDRA may file with
the SEC and/or send to its stockholders in connection with the Proposed Transactions. INVESTORS
AND STOCKHOLDERS OF ENDRA ARE URGED TO READ THE FORM S-4, THE PROXY
STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC,
AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY
AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT ENDRA, ASP ISOTOPES, RENERGEN, NOBLE
AFRICA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS. Investors and stockholders
will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by
ENDRA and ASP Isotopes with the SEC (when they become available) through the website maintained
by the SEC at www.sec.gov. ENDRA's Internet website address is www.endrainc.com. ENDRA's
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including
exhibits, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Exchange Act are available free of charge through the investor relations page of its Internet website as
soon as reasonably practicable after it electronically files such material with, or furnishes such material
to, the SEC.
Participants in the Solicitation
ENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers and
certain of their executive officers and other members of management may be deemed to be participants
in the solicitation of proxies from ENDRA's stockholders in connection with the Proposed Transactions
under the rules of the SEC. Information about ENDRA's directors and executive officers, including a
description of their interests in ENDRA, is included in ENDRA's most recent Annual Report on Form
10-K for the year ended December 31, 2025. Information about ASP Isotopes' directors and executive
officers, including a description of their interests in ASP Isotopes, is included in ASP Isotopes' most
recent Annual Report on Form 10-K for the year ended December 31, 2025. Additional information
regarding the persons who may be deemed participants in the proxy solicitations, including the directors
and executive officers of Renergen, and a description of their direct and indirect interests, by security
holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant
materials to be filed with the SEC when they become available. These documents can be obtained free
of charge from the sources indicated above.
No Offer or Solicitation
This press release is not intended to and does not constitute a solicitation of a proxy, consent or
approval with respect to any securities or in respect of the Proposed Transactions or an offer to sell or
the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any
securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or
transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall
be made except by means of a prospectus meeting the requirements of Section 10 of the Securities
Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom.
Subject to certain exceptions to be approved by the relevant regulators or certain facts to be
ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do
so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means
or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of
interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead, they are based only on the
Company's current beliefs, expectations, and assumptions regarding the future of the Company's
business, future plans and strategies, projections, anticipated events and trends, the economy, and
other future conditions. Forward-looking statements can be identified by words such as "anticipates,"
"believes," "could," "estimates," "expects," "intends," "may," "might," "plans," "projects," "will," and words
of a similar nature. Examples of forward-looking statements include, but are not limited to, statements
regarding the Company's business strategy and market opportunity, and expectations regarding the
structure, timing and completion of the Proposed Transactions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that
are difficult to predict, many of which are outside of the Company's control. Actual results, financial
condition, and events may differ materially from those indicated in the forward-looking statements based
upon a number of factors. Forward-looking statements are not a guarantee of future performance or
developments. You are strongly cautioned that reliance on any forward-looking statements involves
known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-
looking statements.
There are many important factors that could cause actual results and financial condition to differ
materially from those indicated in the forward-looking statements, including, but not limited to: the
outcomes of various strategies and projects undertaken by the Company; the potential impact of laws
or government regulations or policies in South Africa, the United Kingdom or elsewhere; the Company's
future capital requirements and sources and uses of cash; the Company's ability to obtain funding for
its operations and future growth; the Company's reliance on the efforts of third parties; the Company's
ability to complete the construction and commissioning of its enrichment plants or to commercialize
isotopes using the ASP technology or the Quantum Enrichment Process; the Company's ability to obtain
regulatory approvals for the production and distribution of isotopes; the financial terms of any current
and future commercial arrangements; the Company's ability to complete certain transactions and
realize anticipated benefits from acquisitions and contracts; dependence on the Company's Intellectual
Property (IP) rights, certain IP rights of third parties; the competitive nature of the Company's industry;
the risk that the conditions to the closing or consummation of the Proposed Transactions are not
satisfied, including the failure to timely obtain approval of the Proposed Transactions from ENDRA
stockholders, if at all; uncertainties as to the timing of the consummation of the Proposed Transactions
and the ability of each of ENDRA and Noble Africa to consummate the Proposed Transactions; and the
other risks and uncertainties disclosed in Part I, Item 1A. "Risk Factors" of the Company's Annual Report
on Form 10-K for the fiscal year ended December 31, 2025 (as amended) and in the Company's
subsequent reports filed with the SEC.
Any forward-looking statement made by the Company in this press release is based only on information
currently available to the Company and speaks only as of the date on which it is made. The Company
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new
information, future developments or otherwise. No information in this press release should be
interpreted as an indication of future success, revenues, results of operations, or stock price. All
forward-looking statements herein are qualified by reference to the cautionary statements set forth
herein and should not be relied upon.
Contact
IR@ASPIsotopes.com
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the
JSE.
28 July 2026
Sponsor
Valeo Capital Proprietary Limited
Date: 28-07-2026 02:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
